首页> 外文期刊>Nanobiotechnology, IET >Development of tamoxifen-loaded surface-modified nanostructured lipid carrier using experimental design: in vitro and ex vivo characterisation
【24h】

Development of tamoxifen-loaded surface-modified nanostructured lipid carrier using experimental design: in vitro and ex vivo characterisation

机译:使用实验设计的制革罗素装载的表面改性纳米结构脂质载体的研制:体外和离体表征

获取原文
获取原文并翻译 | 示例
           

摘要

The present study aimed to develop a surface-modified biocompatible nanostructured lipid carrier (NLCs) system using polyoxyethylene (40) stearate (POE-40-S) to improve the oral bioavailability of poorly water-soluble Biopharmaceutics Classification System class-II drug like tamoxifen (TMX). Also aimed to screen the most influential factors affecting the particle size (PS) using Taguchi (L-12 (2(11))) orthogonal array design (TgL(12)OA). Then, to optimize the TMX loaded POE-40-S (P) surface-modified NLCs (TMX-loaded-PEG-40-S coated NLC (PNLCs) or PNLCs) by central composite design (CCD) using a four-factor, five-level model. The most influential factors affecting the PS was screened and optimized. The in-vitro study showed that increased drug-loading (DL) and encapsulation efficiency (EE), decreased PS and charge, sustained drug release for the prolonged period of the time with good stability and suppressed protein adsorption. The Ex-vivo study showed that decreased mucous binding with five-fold enhanced permeability of PNLC formulation after surface modification with POE-40-S. The in-vitro cytotoxicity study showed that the blank carrier is biocompatible and cytotoxicity of the formulation was dependent on the concentration of the drug. Finally, it can be concluded that the surface-modified PNLCs formulation was an effective, biocompatible, stable formulation in the enhancement of dissolution rate, solubility, stability with reduced mucus adhesion and increased permeability thereby which indicates its enhanced oral bioavailability.
机译:本研究旨在使用硬脂酸盐(PoE-40-S)的聚氧乙烯(40)型含有聚氧乙烯(40)的表面改性的生物相容性纳米结构脂质载体(NLCS)系统,以改善水溶性生物食品植物分类系统类-II类药物的口服生物利用度如Tamoxifen (TMX)。还旨在筛选使用Taguchi(L-12(2(11)))正交阵列设计(TG1(12)OA)影响粒度(PS)的最有影响力的因素。然后,通过四因素,通过中央复合设计(CCD)来优化TMX加载的PoE-40-S(P)表面修改的NLC(TMX加载-PEG-40-S涂覆的NLC(PNLC)或PNLC),五级模型。影响和优化影响PS的最有影响力的因素。体外研究表明,药物负载(DL)和包封效率(EE)增加,PS和电荷减少,持续的药物释放,延长的时间稳定性和抑制蛋白质吸附。前体内研究表明,用POE-40-S表面改性后,与PNLC制剂的五倍增强渗透性降低了浊度。体外细胞毒性研究表明,空白载体是生物相容性的,配方的细胞毒性取决于药物的浓度。最后,可以得出结论,表面改性的PNLC制剂是一种有效,生物相容性,稳定的制剂,可提高溶解速率,溶解度,具有降低的粘液粘附性和增加的渗透性,从而表明其增强的口腔生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号